The Protein Chemistry Laboratory Core (PCLC) will serve as the major protein preparation and analysis resource for the Program Project. The laboratory will be responsible for protein preparation, characterization and identification, which will include project-driven proteomics. The PCLC is equipped with a peptide synthesizer, a lyophilizer, and various fast protein liquid chromatography (FPLC), high-performance LC (HPLC) and ultra-performance LC (UPLC) systems encompassing both micro and macro scales. Most importantly, the laboratory has a "proteomics-appropriate" mass spectrometry (MS) system equipped with ionization modes that will enable sub-picomole analysis of proteins, peptides, and post-translational modifications (PTM) with bio-informatics support. All protein and peptide products will be subjected to stringent characterization by mass spectrometric/proteomic analysis. Surface plasmon resonance (Biacore) analysis is also available that is adaptable to coupling with the on-site mass spectrometers. The primary services provided will be the provision of protein-related tools and reagents such as purified complement system proteins, antibodies, synthetic peptides, and peptide-like synthetic antagonists that interrupt various and specific complement system protein-protein interactions. In addition, the PCLC will perform MS-based analyses of these reagents along with comprehensive sample analysis and high-throughput screening of PTM related to complement/inflammatory processes. All members of the Program Project will be served by the PCLC.
The Protein Chemistry Laboratory Core (PCLC) will provide all of the projects of this proposal with protein and peptide reagents, including proteins and inhibitors of the complement system, an important part of innate immunity. The PCLC will characterize these products to ensure purity and quality and analyze experimental samples from the various projects through mass spectrometric analyses. These activities of the PCLC are vital for each of the projects to ensure efficient, reliable, and cost-effective research.
|Lamont, Richard J; Hajishengallis, George (2015) Polymicrobial synergy and dysbiosis in inflammatory disease. Trends Mol Med 21:172-83|
|Rafail, Stavros; Kourtzelis, Ioannis; Foukas, Periklis G et al. (2015) Complement deficiency promotes cutaneous wound healing in mice. J Immunol 194:1285-91|
|Reis, Edimara S; DeAngelis, Robert A; Chen, Hui et al. (2015) Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 220:476-82|
|Maekawa, Tomoki; Krauss, Jennifer L; Abe, Toshiharu et al. (2014) Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe 15:768-78|
|Klapper, Yvonne; Hamad, Osama A; Teramura, Yuji et al. (2014) Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials 35:3688-96|
|Huang, Yijun; Reis, Edimara S; Knerr, Patrick J et al. (2014) Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. ChemMedChem 9:2223-6|
|Pio, Ruben; Corrales, Leticia; Lambris, John D (2014) The role of complement in tumor growth. Adv Exp Med Biol 772:229-62|
|Maekawa, Tomoki; Abe, Toshiharu; Hajishengallis, Evlambia et al. (2014) Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J Immunol 192:6020-7|
|Mastellos, Dimitrios C; Ricklin, Daniel; Yancopoulou, Despina et al. (2014) Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol 7:583-98|
|Clarkson, Benjamin D S; Ling, Changying; Shi, Yejie et al. (2014) T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice. J Exp Med 211:595-604|
Showing the most recent 10 out of 130 publications